770719-22-7

Basic information

• Product Name: (2,5-difluoro-4-nitrophenyl)acetic acid
• Synonyms: (2,5-difluoro-4-nitrophenyl)acetic acid;2-(2,5-Difluoro-4-nitrophenyl)acetic Acid
• CAS NO: 770719-22-7
• Molecular Weight: 217.129
• Mol File: 770719-22-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (2,5-difluoro-4-nitrophenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2,5-difluoro-4-nitrophenyl)acetic acid(770719-22-7)
• EPA Substance Registry System: (2,5-difluoro-4-nitrophenyl)acetic acid(770719-22-7)

Safety Data

• Hazardous Substances Data: 770719-22-7(Hazardous Substances Data)

Usage

Description

(2,5-difluoro-4-nitrophenyl)acetic acid is a chemical compound with the molecular formula C8H5F2NO4. It is a derivative of phenylacetic acid and contains two fluorine atoms and a nitro group attached to the phenyl ring. (2,5-difluoro-4-nitrophenyl)acetic acid is characterized by its unique structure and properties, making it a versatile building block in the synthesis of various pharmaceuticals and agrochemicals.

Uses

Used in Pharmaceutical Synthesis:
(2,5-difluoro-4-nitrophenyl)acetic acid is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Synthesis:
(2,5-difluoro-4-nitrophenyl)acetic acid is also used in the synthesis of agrochemicals, contributing to the development of new pesticides and herbicides with enhanced performance and reduced environmental impact.
Used in Medical Research:
(2,5-difluoro-4-nitrophenyl)acetic acid has been studied for its potential anti-inflammatory and analgesic properties, making it a promising candidate for the development of new treatments for pain and inflammation.
Used in Cancer Treatment Research:
Furthermore, (2,5-difluoro-4-nitrophenyl)acetic acid has been explored for its potential use in the treatment of cancer and other diseases, highlighting its importance in medical and pharmaceutical research for the development of novel therapeutic agents.

Upstream product

• 2105-61-5 1,2,4-trifluoro-5-nitrobenzene 
• 1034025-91-6 1,3-diethyl (2,5-difluoro-4-nitrophenyl)propanedioate 

Downstream Products

• 1260893-58-0 2-(4-amino-2,5-difluorophenyl)acetic acid 
• 1374573-64-4 [2,5-difluoro-4-(1H-tetrazol-1-yl)phenyl]acetic acid 
• 209995-38-0 (2,4,5-trifluorophenyl)acetic acid 
• 317356-87-9 ethyl 2,5-difluoro-4-nitrophenylacetate 

Relevant articles and documents

A 2, 4, 5-trifluorophenylacetic acid method for the preparation of

The invention discloses a preparation method 2,4,5-trifluorophenylacetic acid. The method is characterized by consisting of four reaction steps of: A, reaction of 2,4,5-trifluoronitrobenzene (I) and diethyl malonate which are condensed to prepare 2,5-difloro-4-nitrobenzophenone diethyl malonate; B, hydrolysis, acidification and decarboxylic reaction of dibasic ester; C, reduction reaction of nitryl; and D, diazotization fluoridation of amino. The four reaction steps can be sequentially carried out according to A, B, C and D, or A, C, B and D, or A, C, D and B. According to the preparation method provided by the invention, condensation of 2,4,5-trifluoronitrobenzene (I) and diethyl malonate is easy to realize by means of high substituting activity of nitryl p-fluorine, and the raw material 2,4,5-trifluoronitrobenzene (I) is low in cost and easy to obtain and can be easily prepared by nitration and fluorination of 2,4-dichlor fluorbenzene. Compared with the prior art, the preparation method provided by the invention has the characteristics of low-cost and easily obtained raw materials, mild reaction condition, high total yield, low production cost and the like, and is comparatively suitable for industrialized production.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

Non-nucleoside reverse transcriptase inhibitors

This invention relates to novel pyridazinone derivatives of formula I wherein R1-R4, R7, R8 and X1 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient and processes to prepare compounds of formula I. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated